Effect of Delayed Cell Infusion in Patients With Large B-Cell Lymphoma Treated With Chimeric Antigen Receptor T-Cell Therapy

Scientists performed a retrospective analysis of 240 patients with relapsed/refractory large B-cell lymphoma treated with standard-of-care axicabtagene ciloleucel (and identified 40 patients (16.7%) who had delay in axi-cel infusion.